These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27184930)

  • 21. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L;
    J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?
    Basaraba JE; Barry AR
    Am J Health Syst Pharm; 2016 May; 73(9):e229-37. PubMed ID: 27099329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
    Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction.
    Veron-Esquivel D; Batiz-Armenta F; Cazares-Diazleal AC; Oviedo-Moguel S; Jarvio-Fernandez SM; Arce-Gonzalez JM; Ivey-Miranda JB
    Hellenic J Cardiol; 2019; 60(5):296-302. PubMed ID: 29807194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.
    Valgimigli M; Cao D; Angiolillo DJ; Bangalore S; Bhatt DL; Ge J; Hermiller J; Makkar RR; Neumann FJ; Saito S; Picon H; Toelg R; Maksoud A; Chehab BM; Choi JW; Campo G; De la Torre Hernandez JM; Kunadian V; Sardella G; Thiele H; Varenne O; Vranckx P; Windecker S; Zhou Y; Krucoff MW; Ruster K; Zheng Y; Mehran R;
    J Am Coll Cardiol; 2021 Nov; 78(21):2060-2072. PubMed ID: 34794687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    Palmerini T; Della Riva D; Benedetto U; Bacchi Reggiani L; Feres F; Abizaid A; Gilard M; Morice MC; Valgimigli M; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Colombo A; Chieffo A; Sangiorgi D; Biondi-Zoccai G; Généreux P; Angelini GD; Pufulete M; White J; Bhatt DL; Stone GW
    Eur Heart J; 2017 Apr; 38(14):1034-1043. PubMed ID: 28110296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Mauri L; Kirtane AJ; Windecker S; Yeh RW; Dauerman HL; Price MJ; Christen T; Allocco DJ; Meredith IT; Kereiakes DJ
    Am Heart J; 2018 Nov; 205():110-117. PubMed ID: 30218844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding versus thrombosis: role of short DAPT in complex lesions.
    Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
    Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.
    Costa F; van Klaveren D; James S; Heg D; Räber L; Feres F; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Zanchin T; Palmerini T; Wallentin L; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    Lancet; 2017 Mar; 389(10073):1025-1034. PubMed ID: 28290994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
    Harada Y; Michel J; Lohaus R; Mayer K; Emmer R; Lahmann AL; Colleran R; Giacoppo D; Wolk A; Ten Berg JM; Neumann FJ; Han Y; Adriaenssens T; Tölg R; Seyfarth M; Maeng M; Zrenner B; Jacobshagen C; Wöhrle J; Kufner S; Morath T; Ibrahim T; Bernlochner I; Fischer M; Schunkert H; Laugwitz KL; Mehilli J; Byrne RA; Kastrati A; Schulz-Schüpke S
    Thromb Haemost; 2017 Oct; 117(10):1989-1999. PubMed ID: 28783201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies.
    Yoshikawa Y; Shiomi H; Watanabe H; Natsuaki M; Kondo H; Tamura T; Nakagawa Y; Morimoto T; Kimura T
    Circulation; 2018 Feb; 137(6):551-562. PubMed ID: 28982692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
    Collet JP; Silvain J; Barthélémy O; Rangé G; Cayla G; Van Belle E; Cuisset T; Elhadad S; Schiele F; Lhoest N; Ohlmann P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
    Lancet; 2014 Nov; 384(9954):1577-85. PubMed ID: 25037988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI.
    Giustino G; Chieffo A; Palmerini T; Valgimigli M; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Gilard M; Morice MC; Sawaya F; Sardella G; Genereux P; Redfors B; Leon MB; Bhatt DL; Stone GW; Colombo A
    J Am Coll Cardiol; 2016 Oct; 68(17):1851-1864. PubMed ID: 27595509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK;
    JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.
    Choi HI; Ahn JM; Kang SH; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1075-1085. PubMed ID: 28527773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.